Neon Therapeutics Names R&D President

Richard Gaynor, M.D., has been appointed president of research and development at Neon Therapeutics, an immuno-oncology company developing neoantigen-based therapeutic vaccines and T cell therapies to treat cancer. Dr. Gaynor succeeds interim chief scientific officer Robert Tepper, M.D., a partner at Third Rock Ventures, who is continuing as a member of the company’s board.
 
Dr. Gaynor recently retired from Eli Lilly’s oncology division, where he served as senior vice president of global product development and medical affairs since 2013. Over the past 15 years he held related senior roles at Lilly Oncology, where he led preclinical and early clinical research, directed the biomarker and research group and served on key company portfolio review committees.
 
“We are privileged to have Richard join the Neon Therapeutics team,” said Hugh O’Dowd, chief executive officer of Neon Therapeutics. “Richard brings an enormous depth of oncology experience, having overseen many innovative drugs through early research into clinical development and commercialization. His knowledge and leadership reinforces Neon Therapeutics’ leadership in neoantigen-based immuno-oncology treatments.”